Navigation Links
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
Date:11/13/2009

STOCKHOLM, November 13 /PRNewswire/ -- Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA. The clinical trial is being conducted in Sweden on advanced-stage cancer patients with documented progressive solid tumors and no remaining treatment options. The first part of the trial has been successfully completed and showed that AXL1717 can be administered as a single-day BID treatment in very high doses without dose-limiting toxicity. The second part of the trial is ongoing and the patients are now being given AXL1717 daily for 7-28 days BID. Results so far show that AXL1717 can be taken in a multidose setting with good tolerability.

"We are very excited about our new clinical data on AXL1717 and pleased to be able to present them at this important scientific meeting" says Johan Harmenberg, CEO of Axelar AB. "Of particular interest is that even though the clinical trial so far was not designed to demonstrate efficacy, a number of patients show signs of tumor necrosis on PET (positron emission tomography). Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may become an effective and well-tolerated treatment alternative for cancer patients in the future".

About AXL1717, the IGF-1 Receptor and Cancer

AXL1717 is an orally administered small-molecule IGF-1 receptor inhibitor with no effect on the important and almost identical insulin receptor. Pre-clinical data on AXL1717 have shown an extraordinary anti-tumor efficacy in animal models, including complete regression of a wide range of human cancers.

The IGF-1 receptor is a validated target for anticancer treatment, the recept
'/>"/>

SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Computing researchers at Houston,s Rice University and electronics ... announced the formation of a $2.6-million Institute for ... at 4 million Singapore dollars, aims to slash ... -- special-purpose computer chips that power everything from ...
... Presented at the 12th World Conference on Lung ... 4 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI ... that identifies,develops and commercializes differentiated products for patients ... two cohorts of,the Phase I part of a ...
... 4 The Cytokine Institute (TCI), a Los,Angeles-based ... the opening of a new office in the ... measures and analyzes the effects of,chemical and toxic ... Boston-based consulting arm, Green Reach Consulting, TCI now ...
Cached Biology Technology:Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 4YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 5Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2
(Date:7/31/2014)... make a rational choice to be liberal or conservative? ... a matter of genetics?, Two political scientists from the ... say that neither conscious decision-making nor parental upbringing fully ... right. , A growing body of evidence shows that ... of political differences, the researchers say in the latest ...
(Date:7/31/2014)... the U.S. surgeon general issued a 101-page report about ... University published a paper breaking new ground on how ... responds when exposed to ultraviolet (UV) light. , The ... UV rays found in sunlight. This damage can lead ... , "Our paper advances foundational knowledge about how ...
(Date:7/31/2014)... Florida State University researcher found that bacteria in the ... of the oil released during the Deepwater Horizon spill ... most toxic contaminants. , In two new studies conducted ... found a species of bacteria called Colwellia ... and xylene compounds that were released as part of ...
Breaking Biology News(10 mins):Scientists find growing consensus: Political attitudes derive from body and mind 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... This press release is available in French ... a whole lot safer for consumers, thanks to Concordia University ... substances in dairy and other products. "Even though Canada ... antibiotics in cows, until now there were no methods or ...
... basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist ... at the Institut de recherches cliniques de Montral (IRCM), and ... patents awarded to the institute and covering different uses of ... Schiller,s laboratory at the IRCM. A total of ...
... OAK RIDGE, Tenn. -- A tree outside Oak Ridge ... inspiration for a discovery that may ultimately lead to ... more. Just as a breeze causes leaves, branches ... the molecular level perform hundreds of chemical processes that ...
Cached Biology News:Discovery of therapeutic peptides affecting mitochondria 2ORNL fundamental discovery casts enzymes in new light 2
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
... J. Davison and Richard ... Contents include: information on ... paramyxoviruses, influenza and immunodeficiency ... analysis of viral NA ...
...
...
Biology Products: